Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101 at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that an oral presentation, "The Therapeutic Potential of EVX-101 to Amplify Serotonin Synthesis for the Adjunctive Treatment of MDD and Other Mental Illness: Emerging Profile and Post-Phase 1 Update", will be presented during the Pharmaceutical Pipeline Session on May 30^th by Dr. Jacobson, Chief Scientific Officer, at the 2023 ASCP Meeting in Miami Beach, FL.

In addition, a poster (T30) presentation, "A Phase 1 SAD and MAD Trial of EVX-101, A Novel Gastro-Retentive Prolonged-Release 5-HTP/Low-Dose Carbidopa Tablet, in Healthy Subjects Taking Escitalopram" will be presented during Poster Session II from 12:30 pm ? 2:15 pm on Thursday, June 1^st by David Carpenter, PharmD, Executive Director, Clinical Development.

"We are excited to present the Phase 1 data on EVX-101 in combination with a first-line serotonin reuptake inhibitor in healthy volunteers. The data support the use of EVX-101 as a first-choice therapy among next-line antidepressants and could provide a safe and efficacious option for MDD patients not responding to monotherapy with first-line serotonin reuptake inhibitors," remarked Jacob Jacobsen, PhD, Chief Scientific Officer of Evecxia Therapeutics.

About Evecxia Therapeutics

Evecxia's mission is to help patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate. Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification differs from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy in acute suicidal crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on EVX-101 and EVX-301 related to method of treatment, doses, formulations, and related technologies.

Following the completion of the meeting, the abstracts and posters will be available online at www.evecxia.com.